Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$34.79 USD

34.79
394,289

+0.51 (1.49%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio

by Zacks Equity Research

ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.

J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe

by Zacks Equity Research

J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.

Kinjel Shah headshot

Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe

by Kinjel Shah

The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.

Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study

by Zacks Equity Research

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

by Zacks Equity Research

Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.

Why Is Zoetis (ZTS) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit

by Zacks Equity Research

The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

by Zacks Equity Research

Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.

Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why

by Zacks Equity Research

Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.

Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.

AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication

by Zacks Equity Research

AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

by Zacks Equity Research

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

by Zacks Equity Research

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

by Zacks Equity Research

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

by Zacks Equity Research

Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.

Why Is Corcept (CORT) Up 4.8% Since Last Earnings Report?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal

by Zacks Equity Research

Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.

Alkermes (ALKS) Grants Teva License to Market Generic Drug

by Zacks Equity Research

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.

Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug

by Zacks Equity Research

Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.

J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation

by Zacks Equity Research

With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.

FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%

by Zacks Equity Research

FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.

Vertex (VRTX) Outperforms Industry Year to Date: Here's Why

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio.

Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug

by Zacks Equity Research

Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.